Medicinal composition for treating diabetes and obesity
A composition, obesity technology, applied in the direction of drug combination, metabolic disease, pharmaceutical formulation, etc.
Inactive Publication Date: 2012-02-29
郑飞雄
View PDF1 Cites 1 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0004] Although the current prior art has a combination of adding blood lipid-lowering drugs to hypoglycemic drugs, this combination is mainly due to the hyperlipidemia complications caused by hyperglycemia.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0064] Sitagliptin phosphate (calculated as sitagliptin) 25g, simvastatin 5g;
[0065] Preparation method: Prepare 1000 tablets with the above-mentioned active ingredients according to the conventional method.
Embodiment 2
[0067] Sitagliptin phosphate 25g (calculated as sitagliptin), simvastatin 25g;
[0068] Preparation method: prepare 1000 capsules with the above active ingredients.
Embodiment 3
[0070] Sitagliptin phosphate 50g (calculated as sitagliptin), simvastatin 5g;
[0071] Preparation method: Prepare 1000 dispersible tablets according to the conventional method with the above active ingredients.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention belongs to the technical field of medicinal preparations and particularly relates to a medicinal composition for treating diabetes and obesity and preparation and use thereof. The invention is characterized in that the active ingredient of a single dose of medicine comprises 10 to 90 milligrams of Sitagliptin or salt thereof based on Sitagliptin and 5 to 50 milligrams of Simvastatin or Lovastatin, preferably 25 to 50 milligrams of Sitagliptin or salt thereof and 5 to 25 milligrams of Simvastatin or Lovastatin. The medicinal composition can be prepared into any formulation acceptable in pharmaceutics, preferably oral solid preparation.
Description
technical field [0001] The invention belongs to the technical field of medicines, in particular to a pharmaceutical composition for treating diabetes and obesity, the active ingredients of which are sitagliptin and simvastatin / lovastatin. Background technique [0002] Sitagliptin, alias (3R)-3-amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[ 4,3-a]pyrazin-7-yl]-4-(2,-trifluorophenyl)butan-1-one, clinically used for type 2 diabetes. This drug is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which controls blood sugar levels by protecting endogenous incretins and enhancing their effects. Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1), are incretins released in response to dietary intake. GLP-1 and GIP can increase insulin synthesis and release from pancreatic β cells through intracellular signaling pathways. GLP-1 can also reduce the secretion of glucagon from pancreatic α cells and reduce hepatic glucose production. However,...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K31/4985A61K31/366A61P3/10A61P3/04
Inventor 郑飞雄
Owner 郑飞雄